ReleaseWire

The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

Global Markets Direct's, 'Down Syndrome - Pipeline Review, H1 2014', provides an overview of the Down Syndrome's therapeutic pipeline.

Food Allergy - Pipeline Review, H1 2014

Euromonitor International's Industrial reports provide a 360 degree view of an industry. The Industrial market report offers a comprehensive guide to the size and shape of the Pharmaceuticals market at a national level. It provides the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market - be they new product developments, packaging innovations, economic/lifestyle influences, distribution or pricing issues. Forecasts illustrate how the market is set to change.

Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2014', provides an overview of the Amyotrophic Lateral Sclerosis's therapeutic pipeline.

GlobalData's clinical trial report, "Malignant Ascites Global Clinical Trials Review, H1, 2014" provides data on the Malignant Ascites clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Ascites. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Malignant Ascites. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.

GlobalData's clinical trial report, "Malignant Glioma Global Clinical Trials Review, H1, 2014" provides data on the Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Malignant Glioma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'Molecular Targeting Technologies, Inc. - Product Pipeline Review - 2014', provides an overview of the Molecular Targeting Technologies, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Cilian AG - Product Pipeline Review - 2014', provides an overview of the Cilian AG's pharmaceutical research and development focus.

Global Markets Direct's, 'Major Depressive Disorder - Pipeline Review, H1 2014', provides an overview of the Major Depressive Disorder's therapeutic pipeline.

Global Markets Direct's, 'Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2014', provides an overview of the Cytomegalovirus (HHV-5) Infections's therapeutic pipeline.

GlobalData's clinical trial report, "Lymphoblastic Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the Lymphoblastic Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lymphoblastic Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lymphoblastic Lymphoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'Brain Tumor - Pipeline Review, H1 2014', provides an overview of the Brain Tumor's therapeutic pipeline.

Global Markets Direct's, 'Thesan Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Thesan Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Idiopathic (Essential) Hypertension - Pipeline Review, H1 2014', provides an overview of the Idiopathic (Essential) Hypertension's therapeutic pipeline.

GlobalData's clinical trial report, "Pontine Glioma Global Clinical Trials Review, H1, 2014" provides data on the Pontine Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pontine Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pontine Glioma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'Trino Therapeutics Ltd - Product Pipeline Review - 2014', provides an overview of the Trino Therapeutics Ltd's pharmaceutical research and development focus.

Global Markets Direct's, 'Sangamo BioSciences, Inc. - Product Pipeline Review - 2014', provides an overview of the Sangamo BioSciences, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'HIV-1 Infection - Pipeline Review, H1 2014', provides an overview of the HIV-1 Infection's therapeutic pipeline.

Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.

GlobalData's clinical trial report, "Low-Grade Astrocytoma Global Clinical Trials Review, H1, 2014" provides data on the Low-Grade Astrocytoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Low-Grade Astrocytoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Low-Grade Astrocytoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.

GlobalData's clinical trial report, "Metastatic Breast Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Breast Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Breast Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Breast Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Neuroendocrine Cancer Global Clinical Trials Review, H1, 2014" provides data on the Neuroendocrine Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroendocrine Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroendocrine Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.